Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
GfV 2024
Programm
Poster
Personen
Suche
DE
Zurück
Workshop
Workshop 18
Antiviral therapy and resistance 2
Termin
Datum:
28.03.2024
Zeit:
11:00
–
12:30
Ort / Stream:
Lecture hall 3
Chair
Dr. Jeremy V. Camp
Vienna / AT
Dr. Rolf Kaiser
Cologne / DE
Programm
11:00
–
11:15
12 Min.
3 Min.
Abstract talk
O 106
Characterization of Mpox virus genomes and patient isolates from Franconia (Bavaria, Germany) and antiviral testing of patient isolates
Dr. Arne Cordsmeier (Erlangen / DE)
Antiviral therapy and resistance
11:15
–
11:30
12 Min.
3 Min.
Abstract talk
O 107
Discovery and pre-clinical development of
a novel class of host-directed pan-flavivirus therapeutics: A tale of two
Orthoflavivirus –
Zika and dengue viruses
Professor François Jean (Vancouver / CA)
Antiviral therapy and resistance
11:30
–
11:45
12 Min.
3 Min.
Abstract talk
O 108
NRF2 activators inhibit hepatitis E virus propagation in vitro
Fenja Laue (Hannover / DE)
Antiviral therapy and resistance
11:45
–
12:00
12 Min.
3 Min.
Abstract talk
O 109
Targeting HIV reservoir cells: Enhanced precision for
in vivo
gene delivery through bispecific AAV vectors
Samuel Theuerkauf (Langen / DE)
Antiviral therapy and resistance
12:00
–
12:15
12 Min.
3 Min.
Abstract talk
O 110
Geno2pheno-bNAbs: Interpretable and accurate prediction of HIV bNAb resistance
Dr. Martin Pirkl (Cologne / DE)
Antiviral therapy and resistance
12:15
–
12:30
12 Min.
3 Min.
Abstract talk
O 111
Helicase-primase inhibitor pritelivir for the treatment of resistant HSV infections in immunocompromised patients
Dr. Alexander Birkmann (Wuppertal / DE)
Antiviral therapy and resistance
v1.19.0
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz